- Home
- VRTX vs BMO Comparison
VRTX vs BMO Comparison
Compare VRTX & BMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRTX | BMO |
|---|---|---|
| Founded | 1989 | 1817 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Commercial Banks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 93.6B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRTX | BMO |
|---|---|---|
| Price | $441.30 | $148.76 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 29 | 1 |
| Target Price | ★ $539.69 | $163.00 |
| AVG Volume (30 Days) | ★ 1.2M | 673.3K |
| Earning Date | 05-04-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 3.17% |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 15.32 | N/A |
| Revenue | ★ $2,488,652,000.00 | N/A |
| Revenue This Year | $10.81 | $19.43 |
| Revenue Next Year | $10.41 | $4.27 |
| P/E Ratio | $28.88 | ★ $17.46 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $362.50 | $91.74 |
| 52 Week High | $510.77 | $149.60 |
Technical Indicators
Market Signals| Indicator | VRTX | BMO |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 67.42 |
| Support Level | $427.52 | $129.62 |
| Resistance Level | $442.22 | $149.01 |
| Average True Range (ATR) | 10.82 | 2.20 |
| MACD | 0.78 | 1.64 |
| Stochastic Oscillator | 55.61 | 93.99 |
Price Performance
Historical ComparisonAbout VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About BMO Bank Of Montreal
Bank of Montreal is a diversified financial-services provider based in North America with over CAD 1.4 trillion in assets. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the US.